144 related articles for article (PubMed ID: 7865179)
1. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
3. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
Dyck LE; Boulton AA
Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
[TBL] [Abstract][Full Text] [Related]
4. Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1992 Jun; 216(2):243-7. PubMed ID: 1397011
[TBL] [Abstract][Full Text] [Related]
5. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
6. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
[TBL] [Abstract][Full Text] [Related]
7. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.
Pickar D; Cohen RM; Jimerson DC; Lake CR; Murphy DL
Psychopharmacology (Berl); 1981; 74(1):8-12. PubMed ID: 6791210
[TBL] [Abstract][Full Text] [Related]
8. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
[TBL] [Abstract][Full Text] [Related]
9. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Waldmeier PC
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena.
Sandler M; Glover V; Ashford A; Esmail A
J Neural Transm; 1980; 48(4):241-7. PubMed ID: 6775051
[TBL] [Abstract][Full Text] [Related]
11. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
Bieck PR
Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
[TBL] [Abstract][Full Text] [Related]
12. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
Bieck PR; Antonin KH
J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
[TBL] [Abstract][Full Text] [Related]
13. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
Waldmeier PC; Stöcklin K
Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
[TBL] [Abstract][Full Text] [Related]
14. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
16. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
Garrick NA; Scheinin M; Chang WH; Linnoila M; Murphy DL
Biochem Pharmacol; 1984 May; 33(9):1423-7. PubMed ID: 6203542
[TBL] [Abstract][Full Text] [Related]
19. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
Murphy DL; Karoum F; Pickar D; Cohen RM; Lipper S; Mellow AM; Tariot PN; Sunderland T
J Neural Transm Suppl; 1998; 52():39-48. PubMed ID: 9564606
[TBL] [Abstract][Full Text] [Related]
20. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
Gal S; Abassi ZA; Youdim MB
Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]